OCGN

Ocugen, Inc. is DownToday at 1:04 PM

Ocugen's OCU410 trial shows 31% lesion growth reduction. Results fall short of earlier data, leading to significant stock decline today. I am pulling the plug. When your gene therapy data comes in worse than your earlier data, that's not a trajectory you want to ride.